Fig. 8: ACSL4 is correlated with SPI1 in ccRCC tissue samples.
From: Therapeutic targeting SPI1 in combination with erastin promotes ferroptosis in ccRCC
A The mRNA expression of ACSL4 in normal renal tissues and renal cancer tissues from TCGA-KIRC database. B Overall survival (OS) Kaplan–Meier curve for ACSL4 based on TCGA-KIRC. C qRT‒PCR was used to analyse correlation of SPI1 and ACSL4 mRNA expression in 30 pairs of ccRCC samples (n = 30). D IHC was used to analyse correlation of SPI1 and ACSL4 protein expression in 30 pairs of ccRCC samples (n = 30). E Western blot verification of SPI1 and ACSL4 protein levels in A498, Caki-1, ACHN, 786-O and HK-2 cell lines. F Western blot analysis for the protein levels of SPI1 and ACSL4 in 8 paired clinical samples with ccRCC and adjacent tissues (n = 8). G Immunofluorescence staining of SPI1 (red), ACSL4(green) and DAPI (blue) in 786-O and ACHN. H Article Mechanism Diagram: Knockdown of SPI1 or treatment with UNC1999 both resulted in the restoration of ACSL4 expression in renal cancer cells. Additionally, the combined application of Erastin further enhanced lipid peroxidation, leading to ferroptosis in ccRCC. Data are presented as the mean ± SD and analyzed by t test or Kruskal-Wallis test. *: P < 0.05, **: P < 0.01, ***: P < 0.001.
